Sector News

ATyr slashes headcount, cuts costs after ORCA runs aground

May 14, 2018
Life sciences

ATyr Pharma is laying off 30% of its staff and otherwise cutting its costs in response to lackluster data. The biotech made the cuts after preclinical data on its anticancer antibodies suggested they lack the required efficacy.

San Diego, California-based aTyr made ORCA its third program after identifying a link between the resokine pathway—the backbone of its pipeline—and the ways tumors evade the immune system. The link suggested aTyr could deploy its knowledge of the resokine pathway to develop that most desirable of assets: a drug that makes checkpoint inhibitors more effective.

ATyr’s belief in the theory was brief. Researchers presented initial data on the program at the start of the year, emboldening aTyr to predict a 2019 move into the clinic. Subsequent readouts put pay to that plan.

Details of the data have yet to emerge, but aTyr said what it learned over the past month suggests its ORCA antibodies lack the efficacy to advance. That prompted aTyr to call off IND-enabling activities and layoff staff. ATyr’s diminished resources are now focused on its last hope, ATYR1923.

ORCA’s importance to aTyr grew last year when the biotech made it one of the focal points of its R&D. Resolaris, a treatment for rare muscular dystrophies, used to be the top priority at aTyr, but the company dialed down its interest after getting a look at early clinical data. With Resolaris on the backburner, ORCA and ATYR1923 stepped into the limelight.

The two-pronged R&D focus was short lived, though. ATYR1923 is the only one game in town for the newly slimmed-down aTyr.

“Going forward, we are primarily focused on ATYR1923 and designing a future patient trial which will be influenced by data from our ongoing phase I trial, translational activities and research related to the role of the receptor for ATYR1923,” aTyr CEO Sanjay Shukla, M.D., said in a statement.

ATyr had $74.1 million in the bank as of the end of March.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend